Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Mar 09  •  04:00PM ET
12.91
Dollar change
-0.13
Percentage change
-1.00
%
IndexRUT P/E- EPS (ttm)-1.22 Insider Own10.01% Shs Outstand112.49M Perf Week-4.51%
Market Cap1.47B Forward P/E- EPS next Y-1.16 Insider Trans-1.47% Shs Float102.41M Perf Month27.95%
Enterprise Value1.26B PEG- EPS next Q-0.49 Inst Own84.90% Short Float8.69% Perf Quarter9.78%
Income-136.23M P/S2.24 EPS this Y-23.77% Inst Trans5.22% Short Ratio4.46 Perf Half Y5.13%
Sales655.35M P/B4.27 EPS next Y22.89% ROA-13.32% Short Interest8.90M Perf YTD-0.15%
Book/sh3.03 P/C3.21 EPS next 5Y30.19% ROE-38.89% 52W High21.55 -40.09% Perf Year-36.03%
Cash/sh4.02 P/FCF- EPS past 3/5Y-11.40% - ROIC-23.60% 52W Low9.82 31.47% Perf 3Y-81.74%
Dividend Est.- EV/EBITDA- Sales past 3/5Y6.81% 5.80% Gross Margin74.54% Volatility7.72% 8.81% Perf 5Y-90.14%
Dividend TTM- EV/Sales1.92 EPS Y/Y TTM21.72% Oper. Margin-23.47% ATR (14)1.11 Perf 10Y-9.97%
Dividend Ex-Date- Quick Ratio2.71 Sales Y/Y TTM8.28% Profit Margin-20.79% RSI (14)51.60 Recom1.50
Dividend Gr. 3/5Y- - Current Ratio2.90 EPS Q/Q64.08% SMA205.24% Beta0.75 Target Price25.93
Payout- Debt/Eq0.73 Sales Q/Q8.11% SMA500.98% Rel Volume0.67 Prev Close13.04
Employees1605 LT Debt/Eq0.70 EarningsFeb 26 BMO SMA200-5.29% Avg Volume1.99M Price12.91
IPOOct 02, 2015 Option/ShortYes / Yes EPS/Sales Surpr.46.52% -0.03% Trades Volume1,345,370 Change-1.00%
Date Action Analyst Rating Change Price Target Change
Jul-25-25Downgrade Wells Fargo Overweight → Equal Weight $14.50
Jul-08-25Initiated Ladenburg Thalmann Buy $30
Dec-02-24Upgrade Evercore ISI In-line → Outperform $18 → $30
Oct-16-24Upgrade H.C. Wainwright Neutral → Buy $24 → $30
Nov-20-23Resumed JP Morgan Neutral $15
Aug-28-23Downgrade H.C. Wainwright Buy → Neutral $85 → $25
Aug-08-23Upgrade Piper Sandler Neutral → Overweight $45
Aug-04-23Initiated SVB Securities Outperform $51
Jul-31-23Upgrade Evercore ISI Underperform → In-line $33
Jun-07-23Upgrade Wedbush Underperform → Neutral $53 → $46
Mar-09-26 11:53AM
Mar-02-26 09:15AM
07:00AM
Feb-27-26 04:30PM
Feb-26-26 04:34PM
04:14PM Loading…
04:14PM
12:15PM
09:04AM
07:39AM
07:00AM
Feb-25-26 09:00AM
Feb-24-26 07:00AM
Feb-19-26 10:00AM
Feb-17-26 11:17AM
10:01AM
07:42AM Loading…
Feb-13-26 07:42AM
06:00AM
Feb-12-26 05:43PM
04:35PM
04:15PM
03:11PM
11:26AM
10:07AM
06:53AM
06:28AM
06:19AM
04:50AM
Feb-11-26 09:55PM
06:33PM
05:54PM
08:10AM Loading…
Feb-05-26 08:10AM
Jan-12-26 07:00AM
Jan-07-26 03:58AM
Dec-22-25 07:00AM
Dec-09-25 05:31AM
Dec-01-25 07:00AM
Nov-26-25 07:00AM
Nov-12-25 10:00AM
07:00AM
Oct-30-25 04:22PM
10:30AM
08:20AM
07:17AM
07:00AM
Oct-15-25 07:00AM
Oct-01-25 07:00AM
Sep-29-25 04:30PM
Sep-16-25 05:28AM
Sep-15-25 07:00AM
Aug-29-25 04:26AM
Aug-28-25 07:00AM
Aug-25-25 07:00AM
Aug-22-25 01:37PM
Aug-20-25 07:00AM
Aug-13-25 12:08PM
Jul-25-25 07:02AM
Jul-24-25 01:30PM
08:05AM
07:00AM
Jul-01-25 07:00AM
Jun-30-25 09:32AM
07:00AM
Jun-18-25 12:00PM
Jun-06-25 12:26PM
Jun-02-25 02:05PM
May-31-25 03:08PM
08:00AM
May-28-25 06:57AM
May-27-25 07:00AM
May-16-25 10:00AM
May-15-25 09:55AM
Apr-29-25 09:55AM
Apr-25-25 01:21PM
Apr-24-25 07:03PM
10:34AM
09:30AM
08:15AM
07:13AM
07:00AM
Apr-23-25 10:16AM
06:45AM
Apr-22-25 10:01AM
07:09AM
Apr-17-25 10:01AM
Apr-16-25 03:43PM
Apr-10-25 08:40AM
Apr-01-25 07:00AM
Mar-21-25 05:16PM
Mar-04-25 07:00AM
Feb-28-25 02:09AM
Feb-27-25 03:30PM
10:00AM
08:20AM
07:20AM
07:00AM
Feb-20-25 10:00AM
Jan-30-25 03:14PM
Jan-22-25 04:00AM
Jan-13-25 07:00AM
Jan-03-25 07:00AM
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Leupin NicolasFormer Chief Medical OfficerMar 04 '26Sale13.311,10014,636102,979Mar 05 04:33 PM
Weinberg UriChf Medical and Innovation OfrMar 04 '26Sale13.316,41285,314267,190Mar 05 04:32 PM
Brackmann ChristophChief Financial OfficerMar 04 '26Sale13.316,41285,314182,842Mar 05 04:31 PM
Leonard Frank XChief Executive OfficerMar 04 '26Sale13.315,60774,603493,793Mar 05 04:31 PM
Paravasthu MukundChief Operating OfficerMar 05 '26Sale13.7743,246595,67072,832Mar 05 04:31 PM
Paravasthu MukundChief Operating OfficerMar 04 '26Sale13.315,37771,543116,078Mar 05 04:31 PM
Puri Michal NathChief Human Resources OfficerMar 04 '26Sale13.311,10014,636201,322Mar 05 04:31 PM
DOYLE WILLIAM FExecutive ChairmanMar 03 '26Sale12.9871,887932,883328,397Mar 05 04:30 PM
MUKUND PARAVASTHUOfficerMar 05 '26Proposed Sale13.7743,246595,682Mar 05 04:06 PM
CHRISTOPH BRACKMANNOfficerMar 04 '26Proposed Sale13.316,41285,314Mar 04 05:54 PM
URI WEINBERGOfficerMar 04 '26Proposed Sale13.316,41285,314Mar 04 05:53 PM
MUKUND PARAVASTHUOfficerMar 04 '26Proposed Sale13.315,37771,543Mar 04 05:42 PM
FRANCIS LEONARDOfficerMar 04 '26Proposed Sale13.315,60774,603Mar 04 05:13 PM
WILLIAM DOYLEOfficerMar 03 '26Proposed Sale12.9871,887932,885Mar 03 05:01 PM
Weinberg UriChf Medical and Innovation OfrFeb 27 '26Sale13.847,461103,257213,757Mar 03 04:11 PM
Weinberg UriChf Medical and Innovation OfrMar 02 '26Sale13.333,27243,607223,477Mar 03 04:11 PM
Puri Michal NathChief Human Resources OfficerFeb 27 '26Sale13.661,44119,690162,322Mar 03 04:10 PM
Leonard Frank XChief Executive OfficerFeb 27 '26Sale13.669,734133,003338,011Mar 03 04:09 PM
Leonard Frank XChief Executive OfficerMar 02 '26Sale13.497,23297,581349,400Mar 03 04:09 PM
FRANCIS LEONARDOfficerMar 02 '26Proposed Sale13.497,23297,581Mar 02 05:40 PM
URI WEINBERGOfficerMar 02 '26Proposed Sale13.333,27243,607Mar 02 04:14 PM
FRANCIS LEONARDOfficerFeb 27 '26Proposed Sale13.669,734133,003Feb 27 05:13 PM
URI WEINBERGOfficerFeb 27 '26Proposed Sale13.847,461103,257Feb 27 04:19 PM
Cordova AshleyChief Executive OfficerSep 05 '25Buy12.2281,550996,859437,569Sep 08 07:10 AM
Brackmann ChristophChief Financial OfficerJul 29 '25Buy11.5920,000231,800141,150Jul 30 04:33 PM
Stafford KristinDirectorJun 03 '25Sale17.2899917,2593,054Jun 04 04:26 PM
LEUNG GABRIELDirectorJun 03 '25Sale17.3199917,29781,229Jun 04 04:24 PM
Madden Martin J.DirectorJun 03 '25Sale17.1999917,17618,674Jun 04 04:23 PM
Scannell Timothy JDirectorJun 03 '25Sale17.3299917,2996,018Jun 04 04:22 PM
HILLEMAN JERYL LDirectorJun 03 '25Sale17.2699917,2475,591Jun 04 04:17 PM
Ocean Allyson JDirectorJun 03 '25Sale17.2999917,2693,054Jun 04 04:16 PM
VERNON W ANTHONYDirectorJun 03 '25Sale17.3599917,329167,887Jun 04 04:14 PM
Hung DavidDirectorJun 03 '25Sale17.3099917,28012,195Jun 04 04:11 PM
Leonard Frank XEVP, Pres., Novocure OncologyJun 02 '25Sale17.5030,196528,413168,452Jun 04 04:09 PM
FRANCIS LEONARDOfficerJun 02 '25Proposed Sale19.1130,196577,046Jun 02 04:25 PM
Paravasthu MukundChief Operating OfficerMay 03 '25Sale17.9159210,60483,556May 05 04:17 PM
MUKUND PARAVASTHUOfficerMay 05 '25Proposed Sale17.9159210,604May 05 04:05 PM
ELAN Elanco Animal Health Inc daily Stock Chart
Index- P/E- EPS (ttm)-0.47 Insider Own0.92% Shs Outstand496.98M Perf Week-8.24%
Market Cap11.90B Forward P/E20.50 EPS next Y1.17 Insider Trans0.96% Shs Float492.58M Perf Month-1.52%
Enterprise Value15.50B PEG1.69 EPS next Q0.35 Inst Own108.93% Short Float3.74% Perf Quarter8.87%
Income-232.00M P/S2.52 EPS this Y10.40% Inst Trans-6.06% Short Ratio3.76 Perf Half Y29.90%
Sales4.71B P/B1.82 EPS next Y12.56% ROA-1.79% Short Interest18.41M Perf YTD5.79%
Book/sh13.17 P/C21.84 EPS next 5Y12.12% ROE-3.67% 52W High27.72 -13.64% Perf Year114.90%
Cash/sh1.10 P/FCF41.91 EPS past 3/5Y-43.04% 18.11% ROIC-2.19% 52W Low8.02 198.50% Perf 3Y136.80%
Dividend Est.- EV/EBITDA16.63 Sales past 3/5Y2.25% 7.57% Gross Margin43.48% Volatility3.71% 3.70% Perf 5Y-26.52%
Dividend TTM- EV/Sales3.29 EPS Y/Y TTM-168.20% Oper. Margin5.34% ATR (14)0.95 Perf 10Y-
Dividend Ex-Date- Quick Ratio1.08 Sales Y/Y TTM6.22% Profit Margin-4.92% RSI (14)43.48 Recom1.41
Dividend Gr. 3/5Y- - Current Ratio2.17 EPS Q/Q-3328.40% SMA20-4.83% Beta1.90 Target Price29.46
Payout0.00% Debt/Eq0.63 Sales Q/Q12.16% SMA50-1.80% Rel Volume0.84 Prev Close23.36
Employees9900 LT Debt/Eq0.62 EarningsFeb 24 BMO SMA20021.57% Avg Volume4.90M Price23.94
IPOSep 20, 2018 Option/ShortYes / Yes EPS/Sales Surpr.14.54% 4.67% Trades Volume4,227,108 Change2.48%
Date Action Analyst Rating Change Price Target Change
Jan-22-26Upgrade Piper Sandler Neutral → Overweight
Dec-09-25Initiated Barclays Overweight $30
Nov-21-25Initiated KeyBanc Capital Markets Overweight $27
Nov-19-25Upgrade Argus Hold → Buy $25
Oct-07-25Upgrade JP Morgan Neutral → Overweight $24
Jul-17-25Upgrade Leerink Partners Market Perform → Outperform $18
Jun-26-25Upgrade William Blair Mkt Perform → Outperform
Dec-09-24Initiated UBS Buy $18
Dec-02-24Initiated Leerink Partners Market Perform $14
Sep-19-24Downgrade Morgan Stanley Overweight → Equal-Weight $17 → $15
Feb-26-26 09:56AM
Feb-24-26 04:22PM
03:08PM
02:01PM
12:32PM
11:25AM Loading…
11:25AM
09:30AM
08:15AM
06:38AM
06:27AM
Feb-23-26 10:57AM
Feb-22-26 10:06PM
Feb-19-26 09:15AM
08:00AM
Feb-13-26 09:24AM
06:41AM Loading…
Feb-10-26 06:41AM
Jan-30-26 11:56AM
Jan-28-26 07:50AM
Jan-27-26 04:04PM
Jan-26-26 11:35PM
Jan-22-26 04:36PM
08:00AM
06:00AM
Jan-12-26 06:54PM
Jan-06-26 11:08PM
06:52PM
08:00AM
Dec-31-25 02:00PM
Dec-21-25 10:07AM
Dec-19-25 01:30AM
08:43AM Loading…
Dec-18-25 08:43AM
Dec-16-25 02:05PM
09:40AM
Dec-12-25 12:00PM
Dec-09-25 04:15PM
07:40AM
Nov-24-25 07:00PM
Nov-21-25 01:35PM
Nov-20-25 08:00AM
Nov-14-25 09:03AM
Nov-13-25 08:00AM
Nov-12-25 12:35AM
Nov-11-25 08:46AM
Nov-06-25 12:33AM
Nov-05-25 07:26PM
03:12PM
02:01PM
09:30AM
07:35AM
06:36AM
06:27AM
Nov-03-25 10:19PM
04:28PM
Oct-29-25 10:00AM
Oct-28-25 11:27AM
Oct-27-25 06:27AM
Oct-24-25 05:33PM
04:55PM
12:02AM
Oct-23-25 11:40AM
Oct-22-25 09:40AM
Oct-20-25 02:03PM
Oct-17-25 06:39PM
Oct-16-25 04:32PM
Oct-08-25 12:00PM
Oct-07-25 11:31AM
Oct-06-25 11:40AM
05:15AM
Oct-01-25 08:00AM
Sep-30-25 12:00PM
Sep-24-25 12:01PM
Sep-23-25 07:10PM
06:27AM
Sep-11-25 10:57PM
Sep-08-25 03:35PM
06:27AM
Sep-03-25 02:45PM
Sep-01-25 11:31PM
Aug-27-25 12:31PM
08:00AM
Aug-26-25 06:15PM
08:00AM
Aug-14-25 01:34AM
Aug-12-25 03:25AM
Aug-08-25 06:57PM
11:53AM
Aug-07-25 02:13PM
12:23PM
09:30AM
07:35AM
06:59AM
06:27AM
Aug-06-25 06:15PM
09:15AM
Aug-05-25 11:11PM
Aug-04-25 05:45PM
Jul-31-25 01:16PM
Jul-25-25 03:36PM
Jul-24-25 05:42PM
11:40AM
Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. Its products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, TruCan, AviPro, Baytril, Catosal, Denagard, and Experior. The company was founded in 1954 and is headquartered in Indianapolis, IN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kurzius Lawrence ErikDirectorDec 12 '25Buy21.3010,000213,000131,773Dec 16 04:42 PM
Modi Rajeev A.SEE REMARKSDec 11 '25Buy21.334,50095,985123,082Dec 15 04:43 PM
VanHimbergen Robert MEVP and CFODec 11 '25Buy21.646,950150,426124,233Dec 15 04:42 PM
Simmons Jeffrey NPRESIDENT, CEO AND DIRECTORDec 11 '25Buy21.7522,000478,496167,000Dec 15 04:41 PM
Todd S and Jennifer G Young LiFormer CFOAug 11 '25Proposed Sale16.8249,333830,000Aug 11 03:58 PM
Kurzius Lawrence ErikDirectorMar 11 '25Buy10.2010,000102,000111,459Mar 11 05:13 PM